Clinical Trials
53 trialsNCT06466382 2026-05-05
OVPrecision
Swiss GO Trial Group
Phase NA Recruiting
NCT05659381 2026-04-16
HOTT
GOG Foundation
Phase 3 Recruiting
NCT04111978 2025-09-29
MATAO
Swiss GO Trial Group
Phase 3 Recruiting
NCT01402271 2023-12-11
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT03412630 2023-11-24
Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab
Eastern Cooperative Oncology Group
Phase NA Terminated
NCT01506856 2023-09-15
iPocc
Gynecologic Oncology Trial & Investigation Consortium
Phase 2/3 Completed
NCT00993655 2023-08-28
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00499291 2023-05-25
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
Eastern Cooperative Oncology Group
Phase NA Withdrawn
NCT00886691 2022-02-04
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00888615 2021-10-20
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT01720173 2021-10-20
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
GOG Foundation
Phase 2 Completed
NCT00108745 2021-09-30
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
GOG Foundation
Phase 3 Unknown
NCT00954174 2021-09-30
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
GOG Foundation
Phase 3 Unknown
NCT00030446 2020-04-08
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00010179 2020-04-06
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00028743 2020-04-02
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT00693342 2020-02-24
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
GOG Foundation
Phase 3 Withdrawn
NCT00958698 2019-03-12
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase NA Unknown
NCT01489371 2019-03-12
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 1 Completed
NCT00939809 2019-01-15
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00114166 2018-07-24
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00459290 2018-07-18
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 2 Completed
NCT00569673 2018-07-18
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
GOG Foundation
Phase 2 Completed
NCT01275664 2018-05-22
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
GOG Foundation
Phase NA Terminated
NCT00719303 2018-02-19
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
Phase 3 Unknown
NCT00499252 2018-01-11
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00574951 2018-01-11
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Terminated
NCT01118052 2018-01-11
EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00857545 2017-09-13
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
GOG Foundation
Phase 2 Completed
NCT01039207 2017-09-07
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00551265 2017-07-14
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
GOG Foundation
Phase NA Withdrawn
NCT00872989 2016-12-19
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00671788 2016-04-15
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
GOG Foundation
Phase 2 Completed
NCT00066456 2016-02-11
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 1 Completed
NCT00008138 2016-01-08
S0009
SWOG Cancer Research Network
Phase 2 Completed
NCT00003636 2015-08-05
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00060359 2015-05-08
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 1 Completed
NCT00352300 2014-12-31
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
GOG Foundation
Phase 1 Completed
NCT00814086 2014-12-31
Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
GOG Foundation
Phase 1 Completed
NCT01492920 2014-12-31
Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
GOG Foundation
Phase 3 Withdrawn
NCT01294293 2014-12-25
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
GOG Foundation
Phase 1 Completed
NCT00003120 2014-10-09
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
SWOG Cancer Research Network
Phase 3 Completed
NCT00053833 2013-11-08
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
SWOG Cancer Research Network
Phase 2 Terminated
NCT00263822 2013-08-27
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00002538 2013-08-20
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers
GOG Foundation
Phase 2 Completed
NCT00006235 2013-07-09
Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
Phase 1 Completed
NCT00003380 2013-06-10
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
GOG Foundation
Phase 1 Terminated
NCT00003382 2013-06-10
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
GOG Foundation
Phase 1 Terminated
NCT00369954 2013-06-10
Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
GOG Foundation
Phase 2 Withdrawn
NCT00003385 2013-05-27
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 1 Completed